Business Wire

NetApp Advance Offers Organizations Next Level Hybrid Cloud Flexibility and Efficiency

7.2.2023 16:00:00 EET | Business Wire | Press release

Share

NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the availability of NetApp Advance, a new portfolio of storage programs and guarantees to help customers cost-effectively future proof on-premises environments.

NetApp Advance evolves the storage lifecycle, allowing organizations the possibility to avoid complex, costly, and time-consuming refresh cycles by enabling ongoing, non-disruptive hardware upgrades – and ensures efficient, secure and sustainable storage with new guarantees offered to meet the needs of organizations today.

With simplified storage ownership and management, NetApp Advance can help to eliminate complex, time-consuming, and costly upgrade cycles while staying current with technology innovations. Organizations can choose on-premises or cloud storage options to future-proof environments to scale securely, seamlessly, and non-disruptively as they grow. Advance also brings sustainability and efficiency best practices and capabilities that continually improve energy efficiency and operational performance to reduce carbon footprint.

“NetApp Advance brings peace of mind to forward looking organizations in need of storage solutions that can adapt and scale as their business changes and grows,” said Sandeep Singh, Senior Vice President, Enterprise Storage at NetApp. “With NetApp Advance, we’re offering customers the confidence that their storage investment today will provide the flexibility to meet their hybrid cloud needs for the future.”

New benefits of NetApp Advance include:

  • Reducing the cost, complexity, and disruption of tech refreshes by buying once and evolving continuously.
  • Greatly reducing the risk previously associated with the journey to hybrid cloud with the flexibility to easily scale out to the cloud if or when business demands it.

Part of NetApp Advance, the new NetApp Storage Lifecycle Program offers:

  • No additional cost non-disruptive upgrades to the latest storage controller technology every three, four, or five years
  • Option to upgrade controllers at only incremental cost prior to three-year renewal.
  • Optional capacity refresh allowing customers to replace lower capacity drives as part of a storage refresh, so customers never have to buy the same capacity twice and can achieve a more efficient & sustainable data center footprint.
  • Remotely managed software updates including non-disruptive ONTAP software upgrades packed with new capabilities and enhancements.
  • Premier-level support services, with Active IQ and Cloud Insights that enable full-stack visibility and AIOps to streamline observability of the infrastructure beyond the storage layer in a single interface to quickly pinpoint issues and simplify troubleshooting. While ONTAP Essentials provides detailed overviews of ONTAP inventories, workloads, and data protection.

Additionally, the NetApp Storage Lifecycle Program introduces the NetApp Cloud Advantage Program, which allows organizations to trade in controllers for full credit toward their choice of NetApp cloud solutions to enable easy scale out to the cloud in order to meet changing business demands – and two new guarantees to benefit organizations in need of agile and efficient storage consumption options and models.

NetApp’s 4:1 SAN Storage Efficiency Guarantee offers that if workload efficiency goals are not met, NetApp will rectify this at no cost to the customer. Available for all AFF all-flash systems.*

NetApp will also introduce a new Sustainability SLA for NetApp Keystone customers. Keystone comes standard with 99.999 percent data availability.* Now Keystone will provide a standard Watts/TB for each SLA-based performance level, with service credits available if those targets are not met. This new SLA is planned for availability in the first calendar quarter of 2023 and specific terms and conditions will apply.

With NetApp BlueXP, customers will soon have access to a new, industry-first Sustainability Dashboard – available for preview in the first quarter of NetApp’s fiscal year 2024. This dashboard provides a holistic view of an organization’s IT environment with real data measuring power, energy and heat usage to deliver a sustainability scorecard. By offering actionable insights with AIOps to improve their overall score and reduce their storage carbon footprint, organizations can simply and easily monitor and achieve their IT sustainability goals.

“As a NetApp partner, EVT is helping our joint customers optimize their IT environment and accelerate their journey to the cloud,” said Scott Gelb, Solutions Architect at Enterprise Vision Technologies. “With NetApp’s announcement of NetApp Advance, we’re now perfectly positioned to help customers do just that by providing a flexible path to non-disruptive upgrades of their on-premises hardware systems, or to right-size their hybrid cloud environments as they scale out to any cloud with credits toward their choice of NetApp cloud solutions. By future-proofing their investment with Advance, we can limit risk and offer infrastructure agility as their business evolves.”

NetApp Advance is available today. Also announced today, the upcoming availability of NetApp AFF C-Series, a new family of capacity flash storage options that deliver lower cost all-flash storage, and NetApp AFF A150, a new entry-level storage system in the AFF A-Series family of all-flash systems.

*Terms and conditions will apply.

Additional Resources

About NetApp

NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com

Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye